A1C Level and Future Risk of Diabetes: A Systematic Review
Open Access
- 1 July 2010
- journal article
- review article
- Published by American Diabetes Association in Diabetes Care
- Vol. 33 (7) , 1665-1673
- https://doi.org/10.2337/dc09-1939
Abstract
The use of A1C for the identification of persons with undiagnosed diabetes has been investigated for a number of years (1–3). A1C better reflects long-term glycemic exposure than current diagnostic tests based on point-in-time measures of fasting and postload blood glucose (4,5) and has improved test-retest reliability (6). In addition, A1C includes no requirement for fasting or for the oral glucose tolerance test's 2-h wait. These advantages should lead to increased identification and more timely treatment of persons with diabetes. Recently, an American Diabetes Association (ADA)-organized international expert committee recommended the adoption of the A1C assay for the diagnosis of diabetes at a cut point of 6.5% (7). This cut point was primarily derived from a review of studies that examined the association of A1C values with incident retinopathy, and some of the most influential data were obtained from recently published prospective studies. Retinopathy was chosen as the ultimate criterion because it is among the main complications of diabetes. Identification of the point on the A1C distribution most closely related to future retinopathy will identify persons in the greatest need of interventions for the prevention of diabetes complications. In addition to utility and convenience, A1C could help identify persons at increased risk of developing diabetes. This is an important public health priority since a structured lifestyle program or the drug metformin can reduce the incidence of diabetes by at least 50 and 30%, respectively (8). Ideally, selection of diagnostic cut points for pre-diabetes would be based on evidence that intervention, when applied to the high-risk group of interest, results not only in the prevention of diabetes but also later complications. However, currently there are no trials that can provide data to determine the ideal method for defining cut points. In the absence of such data, expert …Keywords
This publication has 31 references indexed in Scilit:
- Development of a Type 2 Diabetes Risk Model From a Panel of Serum Biomarkers From the Inter99 CohortDiabetes Care, 2009
- International Expert Committee Report on the Role of the A1C Assay in the Diagnosis of DiabetesDiabetes Care, 2009
- Predictors of Development of Diabetes in Patients With Chronic Heart Failure in the Candesartan in Heart Failure Assessment of Reduction in Mortality and Morbidity (CHARM) ProgramDiabetes Care, 2009
- Combined Measurement of Fasting Plasma Glucose and A1C Is Effective for the Prediction of Type 2 DiabetesDiabetes Care, 2009
- Translating the A1C Assay Into Estimated Average Glucose ValuesDiabetes Care, 2008
- The prevention of type 2 diabetesNature Clinical Practice Endocrinology & Metabolism, 2008
- Hemoglobin A1c Predicts Diabetes but Not Cardiovascular Disease in Nondiabetic WomenThe American Journal of Medicine, 2007
- Hemoglobin A1c can be helpful in predicting progression to diabetes after Whipple procedureHPB, 2007
- A combination of HbA1c, fasting glucose and BMI is effective in screening for individuals at risk of future type 2 diabetes: OGTT is not neededJournal of Internal Medicine, 2006
- A Two-Step Strategy for Identification of High-Risk Subjects for a Clinical Trial of Prevention of NIDDMDiabetes Care, 1996